Under the terms of license agreement, Biond could get $1 billion as milestones met; Sanofi will be in charge of commercialization and clinical development

Israeli maker of NexoBrid for the treatment of severe burns signs exclusive marketing and distribution agreement with Emirati conglomerate Ghassan Aboud Group

Venture capital firm has already closed $101 million in commitments from Israeli investors; new fund will invest $20 million to $30 million per round

Syringe with peptides and protein fragments developed by Israel's Mileutis to stimulate immune system and reduce use of antibiotics; investor is US-based NovaQuest

ImmunoBrain Checkpoint's antibody that boosts immune cells' communication with brain seen effective in lab animals; clinical trials in humans to start next year

Compassionate and experimental use of Opaganib in Israel has had 'encouraging results'; by inhibiting enzyme, drug helps reduce inflammation levels and halts virus from replicating

Roche jointly sets up investment program with Israeli life-sciences VC fund aMoon, with the aim to speed up the development of new diagnostic technologies from Israel

The US-Israel Business Initiative of the US Chamber of Commerce calls for partnerships between health care professionals, policymakers, and the private sector

Ben Gurion U prof Itzik Mizrahi plans to engineer microbial communities to reduce climate-warming methane and develop more sustainable methods of creating energy, treating waste

The Israeli life science industry is uniquely poised in the global ecosystem, with the life ecosystem witnessing the sprouting of 1400 companies in the last decade